Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases.
dc.contributor.author | Egyházi, S | |
dc.contributor.author | Margison, Geoffrey P | |
dc.contributor.author | Hansson, J | |
dc.contributor.author | Ringborg, U | |
dc.date.accessioned | 2010-03-30T14:01:15Z | |
dc.date.available | 2010-03-30T14:01:15Z | |
dc.date.issued | 1997-01 | |
dc.identifier.citation | Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases. 1997, 33 (1):129-34 Eur. J. Cancer | en |
dc.identifier.issn | 0959-8049 | |
dc.identifier.pmid | 9071912 | |
dc.identifier.doi | 10.1016/S0959-8049(96)00342-5 | |
dc.identifier.uri | http://hdl.handle.net/10541/95257 | |
dc.description.abstract | In tumour cell lines, an inverse relationship has been shown between susceptibility to the cytotoxic effects of the O6-alkylating agents and the expression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). One of the most effective single agents in chemotherapy of metastatic melanoma is the O6-alkylating drug, dacarbazine. We therefore examined the distribution of MGMT in 37 skin and lymph node melanoma metastases using rabbit antihuman MGMT antiserum. MGMT expression was undetectable in tumours from 2 out of 34 patients and low in 4 further patients. When present, staining was mainly nuclear and showed a marked variation both among tumour cells within the same metastases, between separate metastases in the same patient and between tumours in different patients. MGMT expression determined by immunohistochemistry showed a relation to MGMT activity measurements, but was not related to the number of proliferating cells, as identified by staining with MIB-1 antibody. Tumour cells with moderate to strong immunostaining with MGMT antiserum were significantly more abundant in metastases excised after dacarbazine-based chemotherapy (n = 8) than in those excised before treatment (n = 29). | |
dc.language.iso | en | en |
dc.subject | Skin Cancer | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Aged | |
dc.subject.mesh | Aged, 80 and over | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Cell Division | |
dc.subject.mesh | Cell Nucleus | |
dc.subject.mesh | Dacarbazine | |
dc.subject.mesh | Female | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Immunoenzyme Techniques | |
dc.subject.mesh | Lymphatic Metastasis | |
dc.subject.mesh | Male | |
dc.subject.mesh | Melanoma | |
dc.subject.mesh | Methyltransferases | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | O(6)-Methylguanine-DNA Methyltransferase | |
dc.subject.mesh | Skin Neoplasms | |
dc.title | Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases. | en |
dc.type | Article | en |
dc.contributor.department | Department of Oncology, Karolinska Hospital, Stockholm, Sweden. | en |
dc.identifier.journal | European Journal of Cancer | en |
html.description.abstract | In tumour cell lines, an inverse relationship has been shown between susceptibility to the cytotoxic effects of the O6-alkylating agents and the expression of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). One of the most effective single agents in chemotherapy of metastatic melanoma is the O6-alkylating drug, dacarbazine. We therefore examined the distribution of MGMT in 37 skin and lymph node melanoma metastases using rabbit antihuman MGMT antiserum. MGMT expression was undetectable in tumours from 2 out of 34 patients and low in 4 further patients. When present, staining was mainly nuclear and showed a marked variation both among tumour cells within the same metastases, between separate metastases in the same patient and between tumours in different patients. MGMT expression determined by immunohistochemistry showed a relation to MGMT activity measurements, but was not related to the number of proliferating cells, as identified by staining with MIB-1 antibody. Tumour cells with moderate to strong immunostaining with MGMT antiserum were significantly more abundant in metastases excised after dacarbazine-based chemotherapy (n = 8) than in those excised before treatment (n = 29). |